ロード中...
The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder
Mirabegron, is the only β-3 adrenoreceptor (AR) agonist available for the treatment of overactive bladder (OAB). To assess the efficacy and tolerability of this novel drug therapy, two phase II and six phase III Astellas-sponsored trials have been conducted with over 10,500 adults with OAB recruited...
保存先:
| 出版年: | Ther Adv Urol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4707426/ https://ncbi.nlm.nih.gov/pubmed/26834839 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287215614237 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|